Bosh sahifaATYR • NASDAQ
add
aTyr Pharma Inc
0,78 $
Seans yopilganidan keyin:(1,86%)-0,014
0,76 $
Yopilgan:12-dek, 19:27:08 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
0,77 $
Kunlik diapazon
0,76 $ - 0,80 $
Yillik diapazon
0,64 $ - 7,29 $
Bozor kapitalizatsiyasi
75,52 mln USD
Oʻrtacha hajm
3,18 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
The Motley Fool Canada
3 soat oldin
Buy Canadian: 1 TSX Stock Set to Outperform Global Markets in 2026
2,95%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 190,00 ming | — |
Joriy xarajat | 4,80 mln | 44,03% |
Sof foyda | -25,74 mln | -49,16% |
Sof foyda marjasi | -13,55 ming | — |
Har bir ulushga tushum | -0,26 | -13,04% |
EBITDA | -26,58 mln | -47,95% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 90,20 mln | 36,70% |
Jami aktivlari | 106,65 mln | 16,41% |
Jami passivlari | 26,61 mln | 0,49% |
Umumiy kapital | 80,04 mln | — |
Tarqatilgan aksiyalar | 97,99 mln | — |
Narxi/balansdagi bahosi | 0,93 | — |
Aktivlardan daromad | -64,23% | — |
Kapitaldan daromad | -74,40% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -25,74 mln | -49,16% |
Operatsiyalardan naqd pul | -20,48 mln | -55,62% |
Sarmoyadan naqd pul | -20,38 mln | -213,55% |
Moliyadan naqd pul | 29,62 mln | 28 306,67% |
Naqd pulning sof oʻzgarishi | -11,24 mln | -339,93% |
Boʻsh pul | -10,67 mln | -64,55% |
Haqida
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Tashkil etilgan
1-yan, 2005
Sayt
Xodimlar soni
61
